All Case Study of Tazemetostat on Safety in Participants

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2001220001

Enrollment

145

Registered

2022-04-06

Start date

2021-08-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Follicular

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation 2. Participants treated with tazemetostat

Exclusion criteria

Exclusion criteria: Participants with a history of hypersensitivity to any ingredient of Tazverik

Design outcomes

Primary

Measure	Time frame
Number of participants with adverse drug reactions and Serious adverse drug reactions.	—

Secondary

Measure	Time frame
1. Factors considered to affect myelosuppression and infection. 2.Percentage of participants with overall response	—

Contacts

Public ContactInquiry Service

Eisai Co. Ltd.

eisai-chiken_hotline@hhc.eisai.co.jp+81-120-419-497

Outcome results